Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of ulcerative colitis (UC), with signs and symptoms consistent with UC for at least 3 months prior to the first study intervention administration
Moderate to severely active UC disease activity, defined as a modified Mayo score of 4 through 9, inclusive, with the following minimum subscores:
i) An SF subscore ≥ 1, AND ii) An RB subscore ≥ 1, AND iii) An ES ≥ 2 (endoscopy performed within 60 days of the first study intervention administration).
Report of a previous colonoscopy that documents extent of disease
You may not be if
Current or recent (within 3 months of screening) evidence of fulminant colitis, toxic megacolon, or bowel perforation
Extensive colonic resection or current stoma
Colonic dysplasia that has not been removed
Clareo Health | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
